Yungjin Pharm Co Ltd (003520) - Net Assets
Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has net assets worth ₩90.02 Billion KRW (≈ $61.00 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩246.25 Billion ≈ $166.88 Million USD) and total liabilities (₩156.23 Billion ≈ $105.88 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Yungjin Pharm Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩90.02 Billion |
| % of Total Assets | 36.56% |
| Annual Growth Rate | -1.19% |
| 5-Year Change | -21.52% |
| 10-Year Change | -10.58% |
| Growth Volatility | 6.89 |
Yungjin Pharm Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Yungjin Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Yungjin Pharm Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Yungjin Pharm Co Ltd (2013–2024)
The table below shows the annual net assets of Yungjin Pharm Co Ltd from 2013 to 2024. For live valuation and market cap data, see Yungjin Pharm Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩89.80 Billion ≈ $60.86 Million |
+0.19% |
| 2023-12-31 | ₩89.63 Billion ≈ $60.74 Million |
-0.26% |
| 2022-12-31 | ₩89.87 Billion ≈ $60.90 Million |
-14.32% |
| 2021-12-31 | ₩104.89 Billion ≈ $71.08 Million |
-8.34% |
| 2020-12-31 | ₩114.43 Billion ≈ $77.55 Million |
-1.14% |
| 2019-12-31 | ₩115.75 Billion ≈ $78.44 Million |
+3.71% |
| 2018-12-31 | ₩111.61 Billion ≈ $75.63 Million |
-6.72% |
| 2017-12-31 | ₩119.65 Billion ≈ $81.08 Million |
+12.70% |
| 2016-12-31 | ₩106.17 Billion ≈ $71.95 Million |
+5.72% |
| 2015-12-31 | ₩100.42 Billion ≈ $68.06 Million |
-0.36% |
| 2014-12-31 | ₩100.79 Billion ≈ $68.30 Million |
-1.62% |
| 2013-12-31 | ₩102.45 Billion ≈ $69.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yungjin Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 265.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩107.45 Billion | 119.65% |
| Total Equity | ₩89.80 Billion | 100.00% |
Yungjin Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Yungjin Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grupo Industrial Saltillo S.A.B. de C.V
MX:GISSAA
|
$219.39 Million |
|
A Paradise Acquisition Corp.
NASDAQ:APAD
|
$219.39 Million |
|
Filatex India Limited
NSE:FILATEX
|
$219.56 Million |
|
Udaipur Cement Works Limited
NSE:UDAICEMENT
|
$219.63 Million |
|
TriSalus Life Sciences Inc.
NASDAQ:TLSI
|
$219.34 Million |
|
Jin Air Co Ltd
KO:272450
|
$219.32 Million |
|
Paik Kwang Ind
KO:001340
|
$219.31 Million |
|
StealthGas Inc
F:S6W
|
$219.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yungjin Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 89,632,344,150 to 89,803,131,310, a change of 170,787,160 (0.2%).
- Net income of 1,232,792,240 contributed positively to equity growth.
- Other factors decreased equity by 1,062,005,080.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.23 Billion | +1.37% |
| Other Changes | ₩-1.06 Billion | -1.18% |
| Total Change | ₩- | 0.19% |
Book Value vs Market Value Analysis
This analysis compares Yungjin Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.71x to 3.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩654.21 | ₩1770.00 | x |
| 2018-12-31 | ₩610.23 | ₩1770.00 | x |
| 2019-12-31 | ₩632.89 | ₩1770.00 | x |
| 2020-12-31 | ₩625.68 | ₩1770.00 | x |
| 2021-12-31 | ₩573.48 | ₩1770.00 | x |
| 2022-12-31 | ₩491.38 | ₩1770.00 | x |
| 2023-12-31 | ₩490.08 | ₩1770.00 | x |
| 2024-12-31 | ₩491.02 | ₩1770.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yungjin Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.49%
- • Asset Turnover: 1.08x
- • Equity Multiplier: 2.61x
- Recent ROE (1.37%) is above the historical average (-1.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 11.46% | 7.50% | 0.92x | 1.65x | ₩1.50 Billion |
| 2014 | 0.90% | 0.54% | 0.94x | 1.78x | ₩-9.17 Billion |
| 2015 | 3.37% | 1.99% | 0.88x | 1.93x | ₩-6.66 Billion |
| 2016 | 3.96% | 2.18% | 0.97x | 1.88x | ₩-6.41 Billion |
| 2017 | 1.56% | 0.96% | 0.96x | 1.70x | ₩-10.10 Billion |
| 2018 | -5.47% | -3.27% | 0.95x | 1.76x | ₩-17.26 Billion |
| 2019 | 4.35% | 2.28% | 1.10x | 1.73x | ₩-6.55 Billion |
| 2020 | -0.12% | -0.06% | 1.11x | 1.64x | ₩-11.58 Billion |
| 2021 | -11.04% | -5.91% | 1.01x | 1.85x | ₩-22.07 Billion |
| 2022 | -24.44% | -10.06% | 1.08x | 2.26x | ₩-30.95 Billion |
| 2023 | -4.32% | -1.65% | 1.04x | 2.53x | ₩-12.84 Billion |
| 2024 | 1.37% | 0.49% | 1.08x | 2.61x | ₩-7.75 Billion |
Industry Comparison
This section compares Yungjin Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $417,135,058,503
- Average return on equity (ROE) among peers: 2.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yungjin Pharm Co Ltd (003520) | ₩90.02 Billion | 11.46% | 1.74x | $219.38 Million |
| Dongwha Pharm.Co.Ltd (000020) | $296.94 Billion | 15.83% | 0.24x | $113.83 Million |
| Yuhan Corp. (000100) | $756.45 Billion | 11.87% | 0.32x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.61 Trillion | 6.79% | 0.30x | $59.61 Million |
| Yuyu Pharma (000220) | $73.73 Billion | -0.34% | 0.41x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $123.37 Billion | -4.85% | 0.58x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $164.95 Billion | -2.25% | 0.61x | $76.14 Million |
| Samil Pharm (000520) | $65.75 Billion | -8.13% | 2.44x | $127.90 Million |
| Donga Socio Holdings (000640) | $746.90 Billion | 2.65% | 0.82x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more